Skye Bioscience, Inc. Common Stock (SKYE)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $4.83M
Last updated: Nov 17, 2026 at 11:03 AM ET
Skye Bioscience, Inc. Common Stock (SKYE) Financials: Revenue, Profit and Cash Flow
Skye Bioscience, Inc. Common Stock reported revenue of $0 for the fiscal year ended Dec 31, 2025. That year, net income was -$55.92M, operating cash flow was -$43.06M and free cash flow was -$43.07M. The quarter ended Sep 30, 2026 had net income of $69.13K.
Revenue and Margins
The company reported no revenue in the fiscal year ended Dec 2025, with an operating loss of $58.16M.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $0 | N/A | N/A | N/A | N/A |
| Dec 2024 | $0 | N/A | N/A | N/A | N/A |
| Dec 2023 | $0 | N/A | N/A | N/A | N/A |
| Dec 2022 | $0 | N/A | N/A | N/A | N/A |
| Dec 2021 | $0 | N/A | N/A | N/A | N/A |
| Dec 2020 | $0 | N/A | N/A | N/A | N/A |
| Dec 2019 | $0 | N/A | N/A | N/A | N/A |
| Dec 2018 | $0 | N/A | N/A | N/A | N/A |
| Dec 2017 | $0 | N/A | N/A | N/A | N/A |
| Dec 2016 | N/A | N/A | N/A | N/A | N/A |
Income Statement
In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Sep 2026, net income turned positive after a loss in the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cost of revenue | $723.35K | $298.64K | $124.25K | $115.00K | $34.13K | $1.87K | $1.46K | $1.54K | $8.04K | $14.92K |
| Gross profit | -$723.35K | -$298.64K | -$124.25K | -$115.00K | -$34.13K | -$1.87K | -$1.46K | -$1.54K | -$8.04K | -$14.92K |
| Research and development | $42.36M | $18.70M | $5.82M | $6.01M | $2.93M | $1.94M | $2.24M | $329.97K | $311.30K | $939.04K |
| Operating income | -$58.16M | -$30.19M | -$34.74M | -$18.31M | -$7.85M | -$6.29M | -$6.63M | -$4.69M | -$3.86M | -$4.47M |
| Net income | -$55.92M | -$26.57M | -$37.64M | -$19.48M | -$8.52M | -$6.56M | $1.05M | -$19.19M | -$3.09M | -$3.18M |
| EBITDA | -$55.20M | -$25.29M | N/A | N/A | -$7.72M | -$5.85M | $2.04M | -$4.69M | -$3.08M | N/A |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $163.39K |
| Gross profit | N/A | N/A | -$172.89K | -$180.01K | N/A | -$187.07K | -$177.38K | -$175.29K | -$66.00K | -$29.79K | -$27.56K | -$28.37K |
| Operating income | $26.32K | -$11.06M | -$12.67M | -$14.90M | -$13.26M | -$18.24M | -$11.76M | -$10.67M | -$4.97M | -$8.41M | -$6.15M | -$4.09M |
| Net income | $69.13K | -$10.79M | -$12.51M | -$14.44M | -$12.75M | -$17.62M | -$11.10M | -$9.75M | -$3.90M | -$7.90M | -$5.02M | -$4.42M |
Balance Sheet
As of Dec 2025, cash and equivalents exceeded short-term debt of $189.65K by $5.69M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $28.31M | $72.76M | $11.94M | $9.11M | $9.86M | $2.67M | $2.00M | $1.96M | $557.22K | $323.36K |
| Current assets | $27.09M | $70.83M | $11.65M | $8.94M | $9.61M | $2.66M | $1.99M | $1.95M | $555.81K | $279.49K |
| Cash and equivalents | $5.88M | $68.42M | $1.26M | $1.24M | $8.98M | $2.47M | $1.83M | $1.85M | $259.95K | $64.82K |
| Total liabilities | $8.29M | $4.61M | $14.07M | $12.12M | $3.99M | $2.22M | $1.45M | $17.52M | $1.36M | $1.77M |
| Short-term debt | $189.65K | $182.43K | $4.44M | $1.93M | $2.06M | $64.06K | N/A | N/A | $235.00K | N/A |
| Long-term debt | N/A | N/A | N/A | N/A | N/A | $1.43M | $387.07K | $1.36M | N/A | N/A |
| Shareholder equity | $20.02M | $68.15M | -$2.13M | -$3.01M | $5.86M | $450.79K | $548.06K | -$15.56M | -$800.08K | -$1.45M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $5.07M | $11.03M | $19.42M | $28.31M | $41.32M | $52.16M | $64.79M | $72.76M | $81.54M | $87.26M | $94.84M | $11.94M |
| Total liabilities | $3.71M | $11.53M | $10.40M | $8.29M | $8.49M | $8.48M | $5.54M | $4.61M | $5.73M | $14.45M | $15.95M | $14.07M |
| Cash and equivalents | $4.82M | $8.07M | $8.15M | $5.88M | $18.44M | $23.84M | $46.42M | $68.42M | $67.41M | $74.12M | $83.34M | $1.26M |
| Shareholder equity | $1.36M | -$497.31K | $9.01M | $20.02M | $32.84M | $43.68M | $59.25M | $68.15M | $75.80M | $72.81M | $78.88M | -$2.13M |
Cash Flow
Operating cash flow was negative in the fiscal year ended Dec 2025.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$43.06M | -$25.24M | -$13.95M | -$12.74M | -$6.47M | -$6.05M | -$6.03M | -$3.94M | -$3.30M | -$3.55M |
| Capital expenditures | $6.31K | $1.60M | $12.55K | $28.06K | $90.87K | $7.23K | $7.23K | $4.38K | $19.65K | $11.12K |
| Free cash flow | -$43.07M | -$26.84M | -$13.96M | -$12.77M | -$6.57M | -$6.06M | -$6.04M | -$3.95M | -$3.32M | -$3.56M |
| Investing cash flow | -$19.50M | -$245.62K | $6.60M | $5.21M | -$90.87K | -$7.23K | -$7.23K | -$4.38K | -$19.65K | -$11.12K |
| Financing cash flow | $29.57K | $83.56M | $16.44M | -$208.79K | $13.08M | $6.70M | $6.00M | $5.54M | $3.51M | $407.67K |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$5.13M | -$7.12M | -$8.56M | -$9.77M | -$13.36M | -$10.75M | -$9.19B | -$8.17M | -$5.26M | -$7.09M | -$4.71M | -$3.84M |
| Capital expenditures | $3 | $0 | $3 | $3 | $5 | $3 | $6.31M | $50.02K | $1.52M | $32.46K | $3.18K | $7.01K |
| Free cash flow | -$5.13M | -$7.12M | -$8.56M | -$9.77M | -$13.36M | -$10.75M | -$9.19B | -$8.22M | -$6.78M | -$7.13M | -$4.71M | -$3.85M |
Frequently Asked Questions About SKYE
What is Skye Bioscience, Inc. Common Stock's annual revenue?
Skye Bioscience, Inc. Common Stock reported revenue of $0 for the fiscal year ended Dec 31, 2025.
Is Skye Bioscience, Inc. Common Stock profitable?
No. Skye Bioscience, Inc. Common Stock reported net income of -$55.92M for the fiscal year ended Dec 31, 2025.
How much free cash flow does SKYE generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of -$43.06M minus capital expenditures of $6.31K produced free cash flow of -$43.07M.
How much debt does Skye Bioscience, Inc. Common Stock have?
The balance sheet dated Dec 31, 2025 reported short-term debt of $189.65K and cash and equivalents of $5.88M.
SKYE pages: Overview, Earnings, Forecast, Financials, Competitors